Skip to main content
. 2023 Jul 14;15(14):3625. doi: 10.3390/cancers15143625

Figure 3.

Figure 3

Vaccine-related time-to-treatment failure depending on significant clinical variables. (A) Type of cancer diagnosis: others vs. lung cancer; (B) metastatic extent of disease: 1 site vs. ≥2 sites; (C) bone metastatic involvement: not present vs. any; (D) weight loss from baseline: <10% vs. ≥10%; (E) programmed cell death-ligand 1 tumor proportion score (PD-L1 TPS): >1% vs. <1% or unknown; (F) level of NK cell response: high-R (subgroup of patients with NK cell count ≥ 222/µL after the third dose of tozinameran) vs. low-R (subgroup of patients with NK cell count < 222/µL after the third dose of tozinameran).